SlideShare una empresa de Scribd logo
1 de 20
Descargar para leer sin conexión
Dissemination of
Pilot Year Outcomes
Communications Workshop
Work Package 5
DRIVE Annual Forum
18 September 2018
• WP5 introductions
• DRIVE communication channels
• High-level dissemination plan
• Q&A
• Group Activity
• Group Presentations
• Wrap-Up
Agenda
DRIVE Website at www.drive-eu.org
• Features all public deliverables
• Information on Data source, Methodology, Governance model,
Analytical model and Infrastructure of the project
DRIVE on LinkedIn:
https://www.linkedin.com/company
/drive-project/
DRIVE at Twitter: @drive_eu
#DRIVEflu
Web-based survey of PHIs & PHAs
N=7 to date
Current IVE communications adequate: >50% yes
Additional IVE info required: age/risk, type, brand
Recommended communication channels: conferences,
publications, direct, news releases, websites, social media
Frequency: regular/monthly about DRIVE activities
Intention to share DRIVE results with stakeholders: yes
Concerns: 1 about PPP, 1 about reconciliation of DRIVE findings
with findings of other IVE studies
Communications Survey
DRIVE Stakeholders
DRIVE
IMI
European
Science,
Medicine &
Health
Societies
Society at large
ECDC
WHO
EMA
CHMP
Vaccine
Manufacturers
Public Health
Institutes
National
Health
Agencies
European
Commission
European
Patient &
Consumer
Health
Groups
European
Medical &
Nursing
Schools
HCPs
Layer 3
Layer 1
European
Influenza
experts
Research
Partners &
Collaborators
Media
Layer 2
Dissemination Objectives
Primary Objective
Ensure pilot year outcomes are communicated in a
meaningful way to all stakeholder groups
Secondary Objectives
1. Fulfil DRIVE’s commitment to transparency
2. Strengthen the profile and credibilty of DRIVE as public-
private partnership dedicated to brand-specific IVE
3. Recruit additional research partners to DRIVE
4. Stimulate scientific discussion about innovative
approaches to IVE research and potential synergies
Communications Challenges
1. Diverse technical understanding of stakeholders
2. Potential for misinterpretation of IVE estimates
3. Perception of public-private partnerships
3. Uncoordinated disemmination of outcomes
Key Messages
1. DRIVE is an IMI-funded public private partnership
established in 2017 to build a sustainable platform for
generating robust brand-specific influenza vaccine
effectiveness data across Europe each year, as part of
new EMA requirements.
2. DRIVE has established Project Governance, including an
independent scientific review process, and an initial
study platform, which was successfully tested through a
pilot study in the 2017/18 season.
3. DRIVE calls for additional research partners to
contribute data and expertise, enabling the Project to
continue to improve the study platform and to work
towards its longer term goal.
• Study Reports and Summaries
• Results Slide Presentation & Poster
• Infographics
Key Communication Tools
DRIVE Infographic
High Level Plan
Annual
Forum
Sept 17-18
Present Outcomes
Seek feedback on
Communications
approach
Execute Social
Media Plan
Study Reports
Finalised
October
ESCAIDE
Host webinars
Direct email to
Stakeholders
Issues New Release
Load reports onto
DRIVE website
Execute Social
Media Plan
Conferences &
Publications
2019
Direct approach to
potential partners
Annual pooled brand-specific IVE estimates
Systematic review on bias & confounders
Availability & use of brand information
Laboratory methods
Other methodological topics (sample size, pooling
approaches etc.)
The rationale of brand-specific IVE and PPP governance
Scientific independence, intergrity & transparency
Potential publications
Q&A
Acknowledgement
DRIVE project has received funding from the Innovative
Medicines Initiative 2 Joint Undertaking under grant
agreement No 777363, This Joint Undertaking receives
support from the European Union’s Horizon 2020
research and innovation programme and EFPIA.
Communications –
Interactive session
Acknowledgement
DRIVE project has received funding from the Innovative
Medicines Initiative 2 Joint Undertaking under grant
agreement No 777363, This Joint Undertaking receives
support from the European Union’s Horizon 2020
research and innovation programme and EFPIA.
Gael Dos Santos - GSK
18th September 2018, Rome
Instructions
• Each group will brainstorm for 30’ to discuss what your
stakeholder group would like to know from DRIVE
about IVE.
• Prepare a few bullet points for presentation highlighting
the key points.
• Each group will have a slot of 5’ divided as follows:
• At the beginning of the work, each group need to
assign:
- One time keeper
- One scribe/presenter
- The facilitators for each group have been identified
on the list.
Assigned groups
1. Regulatory Authorities – Pieter Neels
2. Public Health Institutes (PHI)/ National and supranational
public health organisations Caterina Rizzo
3. Health Care Professionals - Topi Turunen
4. Researchers/Scientists Group 1 - Margarita Riera
5. Researchers/Scientists Group 2 - Marianne Van der Sande
6. Patients/Patient Organisations - Sam Nye
7. Media - Julien Guyomard
Questions to consider?
- What would I like to know about the DRIVE IVE
and when?
- Are there any particular sensitivities/issues/risks
about communicating to my stakeholder?
- Does the Public Private Partnership matter?
Why?
Questions/proposals

Más contenido relacionado

La actualidad más candente

How to use the EUnetHTA submission template to support production of core Hea...
How to use the EUnetHTA submission template to support production of core Hea...How to use the EUnetHTA submission template to support production of core Hea...
How to use the EUnetHTA submission template to support production of core Hea...EUnetHTA
 
EUnetHTA Training course for Stakeholders - How to use HTA for decision makin...
EUnetHTA Training course for Stakeholders - How to use HTA for decision makin...EUnetHTA Training course for Stakeholders - How to use HTA for decision makin...
EUnetHTA Training course for Stakeholders - How to use HTA for decision makin...EUnetHTA
 
Manning sherrymarketing presentation
Manning sherrymarketing presentationManning sherrymarketing presentation
Manning sherrymarketing presentationSherry3177
 
NHS England share Code4Health Challenge
NHS England share Code4Health ChallengeNHS England share Code4Health Challenge
NHS England share Code4Health ChallengeHANDI HEALTH
 
Is Primary Care Technology Enabled to meet the Primary Care Challenges Ahead?
Is Primary Care Technology Enabled to meet the Primary Care Challenges Ahead?Is Primary Care Technology Enabled to meet the Primary Care Challenges Ahead?
Is Primary Care Technology Enabled to meet the Primary Care Challenges Ahead? NHS England
 
Analysis (TDAs), Progress Monitoring (SAPs) and Indicators Report
Analysis (TDAs), Progress Monitoring (SAPs) and Indicators ReportAnalysis (TDAs), Progress Monitoring (SAPs) and Indicators Report
Analysis (TDAs), Progress Monitoring (SAPs) and Indicators ReportIwl Pcu
 
How to use HTA for decision-making based on HTA Core Information
How to use HTA for decision-making based on HTA Core InformationHow to use HTA for decision-making based on HTA Core Information
How to use HTA for decision-making based on HTA Core InformationEUnetHTA
 
Implications of the external evaluation of the Livestock and Fish value chain...
Implications of the external evaluation of the Livestock and Fish value chain...Implications of the external evaluation of the Livestock and Fish value chain...
Implications of the external evaluation of the Livestock and Fish value chain...ILRI
 
TCIOceania15 WelfareTech - Towards Industrialisation
TCIOceania15 WelfareTech - Towards IndustrialisationTCIOceania15 WelfareTech - Towards Industrialisation
TCIOceania15 WelfareTech - Towards IndustrialisationTCI Network
 
Webinar on EUPATI Guidance on Patient Involvement in Regulatory Processes
Webinar on EUPATI Guidance on Patient Involvement in Regulatory ProcessesWebinar on EUPATI Guidance on Patient Involvement in Regulatory Processes
Webinar on EUPATI Guidance on Patient Involvement in Regulatory ProcessesHibernia College
 
Silvia Stumpf - Key Factors Affecting the Technology Provision of VET in Voca...
Silvia Stumpf - Key Factors Affecting the Technology Provision of VET in Voca...Silvia Stumpf - Key Factors Affecting the Technology Provision of VET in Voca...
Silvia Stumpf - Key Factors Affecting the Technology Provision of VET in Voca...VocTEL Conference
 
Vaccine banks: Policy options evaluated (R. Bergevoet)
Vaccine banks: Policy options evaluated (R. Bergevoet)Vaccine banks: Policy options evaluated (R. Bergevoet)
Vaccine banks: Policy options evaluated (R. Bergevoet)EuFMD
 
OS18 - 3.a.1 Vaccine banks: policy options evaluated using the EU evaluation ...
OS18 - 3.a.1 Vaccine banks: policy options evaluated using the EU evaluation ...OS18 - 3.a.1 Vaccine banks: policy options evaluated using the EU evaluation ...
OS18 - 3.a.1 Vaccine banks: policy options evaluated using the EU evaluation ...EuFMD
 
PC15164_ConferencePreview
PC15164_ConferencePreviewPC15164_ConferencePreview
PC15164_ConferencePreviewDaria Binder
 
Fostering multi-stakeholder Engagement for Impact in FNSSA: some lessons lear...
Fostering multi-stakeholder Engagement for Impact in FNSSA: some lessons lear...Fostering multi-stakeholder Engagement for Impact in FNSSA: some lessons lear...
Fostering multi-stakeholder Engagement for Impact in FNSSA: some lessons lear...Francois Stepman
 
18 andrej gubina horizon 2020.undp.zagreb.12.13.v2.2
18 andrej gubina horizon 2020.undp.zagreb.12.13.v2.218 andrej gubina horizon 2020.undp.zagreb.12.13.v2.2
18 andrej gubina horizon 2020.undp.zagreb.12.13.v2.2UNDPhr
 
Private Sector Collaboration
Private Sector CollaborationPrivate Sector Collaboration
Private Sector CollaborationUWGlobalHealth
 

La actualidad más candente (20)

How to use the EUnetHTA submission template to support production of core Hea...
How to use the EUnetHTA submission template to support production of core Hea...How to use the EUnetHTA submission template to support production of core Hea...
How to use the EUnetHTA submission template to support production of core Hea...
 
EUnetHTA Training course for Stakeholders - How to use HTA for decision makin...
EUnetHTA Training course for Stakeholders - How to use HTA for decision makin...EUnetHTA Training course for Stakeholders - How to use HTA for decision makin...
EUnetHTA Training course for Stakeholders - How to use HTA for decision makin...
 
Manning sherrymarketing presentation
Manning sherrymarketing presentationManning sherrymarketing presentation
Manning sherrymarketing presentation
 
NHS England share Code4Health Challenge
NHS England share Code4Health ChallengeNHS England share Code4Health Challenge
NHS England share Code4Health Challenge
 
Is Primary Care Technology Enabled to meet the Primary Care Challenges Ahead?
Is Primary Care Technology Enabled to meet the Primary Care Challenges Ahead?Is Primary Care Technology Enabled to meet the Primary Care Challenges Ahead?
Is Primary Care Technology Enabled to meet the Primary Care Challenges Ahead?
 
Analysis (TDAs), Progress Monitoring (SAPs) and Indicators Report
Analysis (TDAs), Progress Monitoring (SAPs) and Indicators ReportAnalysis (TDAs), Progress Monitoring (SAPs) and Indicators Report
Analysis (TDAs), Progress Monitoring (SAPs) and Indicators Report
 
How to use HTA for decision-making based on HTA Core Information
How to use HTA for decision-making based on HTA Core InformationHow to use HTA for decision-making based on HTA Core Information
How to use HTA for decision-making based on HTA Core Information
 
Implications of the external evaluation of the Livestock and Fish value chain...
Implications of the external evaluation of the Livestock and Fish value chain...Implications of the external evaluation of the Livestock and Fish value chain...
Implications of the external evaluation of the Livestock and Fish value chain...
 
TCIOceania15 WelfareTech - Towards Industrialisation
TCIOceania15 WelfareTech - Towards IndustrialisationTCIOceania15 WelfareTech - Towards Industrialisation
TCIOceania15 WelfareTech - Towards Industrialisation
 
National initiatives in learning and teaching in Europe
National initiatives in learning and teaching in EuropeNational initiatives in learning and teaching in Europe
National initiatives in learning and teaching in Europe
 
Webinar on EUPATI Guidance on Patient Involvement in Regulatory Processes
Webinar on EUPATI Guidance on Patient Involvement in Regulatory ProcessesWebinar on EUPATI Guidance on Patient Involvement in Regulatory Processes
Webinar on EUPATI Guidance on Patient Involvement in Regulatory Processes
 
Silvia Stumpf - Key Factors Affecting the Technology Provision of VET in Voca...
Silvia Stumpf - Key Factors Affecting the Technology Provision of VET in Voca...Silvia Stumpf - Key Factors Affecting the Technology Provision of VET in Voca...
Silvia Stumpf - Key Factors Affecting the Technology Provision of VET in Voca...
 
Building a KMb Strategy - CECYMH model
Building a KMb Strategy - CECYMH modelBuilding a KMb Strategy - CECYMH model
Building a KMb Strategy - CECYMH model
 
Vaccine banks: Policy options evaluated (R. Bergevoet)
Vaccine banks: Policy options evaluated (R. Bergevoet)Vaccine banks: Policy options evaluated (R. Bergevoet)
Vaccine banks: Policy options evaluated (R. Bergevoet)
 
OS18 - 3.a.1 Vaccine banks: policy options evaluated using the EU evaluation ...
OS18 - 3.a.1 Vaccine banks: policy options evaluated using the EU evaluation ...OS18 - 3.a.1 Vaccine banks: policy options evaluated using the EU evaluation ...
OS18 - 3.a.1 Vaccine banks: policy options evaluated using the EU evaluation ...
 
PC15164_ConferencePreview
PC15164_ConferencePreviewPC15164_ConferencePreview
PC15164_ConferencePreview
 
Fostering multi-stakeholder Engagement for Impact in FNSSA: some lessons lear...
Fostering multi-stakeholder Engagement for Impact in FNSSA: some lessons lear...Fostering multi-stakeholder Engagement for Impact in FNSSA: some lessons lear...
Fostering multi-stakeholder Engagement for Impact in FNSSA: some lessons lear...
 
18 andrej gubina horizon 2020.undp.zagreb.12.13.v2.2
18 andrej gubina horizon 2020.undp.zagreb.12.13.v2.218 andrej gubina horizon 2020.undp.zagreb.12.13.v2.2
18 andrej gubina horizon 2020.undp.zagreb.12.13.v2.2
 
Impact on impact CARA 161014
Impact on impact CARA 161014Impact on impact CARA 161014
Impact on impact CARA 161014
 
Private Sector Collaboration
Private Sector CollaborationPrivate Sector Collaboration
Private Sector Collaboration
 

Similar a Drive communication plan and debate - Sharon McHale & Riia Järvenpää

Dissemination of Pilot Year Outcomes - Communications Workshop, Work Package 5
Dissemination of Pilot Year Outcomes - Communications Workshop, Work Package 5Dissemination of Pilot Year Outcomes - Communications Workshop, Work Package 5
Dissemination of Pilot Year Outcomes - Communications Workshop, Work Package 5DRIVE research
 
Connected health data meets the people: Diversity, Standards, and Trust
Connected health data meets the people: Diversity, Standards, and TrustConnected health data meets the people: Diversity, Standards, and Trust
Connected health data meets the people: Diversity, Standards, and Trustchronaki
 
Communications and Knowledge management in the African Chicken Genetic Gains ...
Communications and Knowledge management in the African Chicken Genetic Gains ...Communications and Knowledge management in the African Chicken Genetic Gains ...
Communications and Knowledge management in the African Chicken Genetic Gains ...ILRI
 
2022 IPPOSI Industry Round Table Presentation
2022 IPPOSI Industry Round Table Presentation2022 IPPOSI Industry Round Table Presentation
2022 IPPOSI Industry Round Table Presentationipposi
 
Introduction to DRIVE - Javier Diez Domingo
Introduction to DRIVE - Javier Diez DomingoIntroduction to DRIVE - Javier Diez Domingo
Introduction to DRIVE - Javier Diez DomingoDRIVE research
 
Roundtable discussion: Relevance of the DRIVE study platform and sustainabili...
Roundtable discussion: Relevance of the DRIVE study platform and sustainabili...Roundtable discussion: Relevance of the DRIVE study platform and sustainabili...
Roundtable discussion: Relevance of the DRIVE study platform and sustainabili...DRIVE research
 
Communications and knowledge management in the African Chicken Genetic Gains ...
Communications and knowledge management in the African Chicken Genetic Gains ...Communications and knowledge management in the African Chicken Genetic Gains ...
Communications and knowledge management in the African Chicken Genetic Gains ...ILRI
 
HSE Digital Academy - Marie Boran, IPPOSI
HSE Digital Academy - Marie Boran, IPPOSIHSE Digital Academy - Marie Boran, IPPOSI
HSE Digital Academy - Marie Boran, IPPOSIipposi
 
Delivering the gender platform’s outcomes: Communications and engagement
Delivering the gender platform’s outcomes: Communications and engagementDelivering the gender platform’s outcomes: Communications and engagement
Delivering the gender platform’s outcomes: Communications and engagementILRI
 
Evaluating the value of research-by-consortium: Science of Team Science
Evaluating the value of research-by-consortium: Science of Team ScienceEvaluating the value of research-by-consortium: Science of Team Science
Evaluating the value of research-by-consortium: Science of Team ScienceMark David Lim
 
Analytics Management Framework
Analytics Management FrameworkAnalytics Management Framework
Analytics Management FrameworkDaniel McKean
 
Euro-FEM Module 5: Promotion and Dissemination Planning
Euro-FEM Module 5: Promotion and Dissemination PlanningEuro-FEM Module 5: Promotion and Dissemination Planning
Euro-FEM Module 5: Promotion and Dissemination PlanningAthanasiaIoannidou
 
EPIS meeting - Dr Derick Mitchell - October 2017
EPIS meeting - Dr Derick Mitchell - October 2017EPIS meeting - Dr Derick Mitchell - October 2017
EPIS meeting - Dr Derick Mitchell - October 2017ipposi
 
AOU Data Collection Process
AOU Data Collection ProcessAOU Data Collection Process
AOU Data Collection ProcessDaniel McKean
 
Alpha One Conference - IPPOSI
Alpha One Conference - IPPOSIAlpha One Conference - IPPOSI
Alpha One Conference - IPPOSIipposi
 
Strengthening research. development and innovation cooperation between jordan...
Strengthening research. development and innovation cooperation between jordan...Strengthening research. development and innovation cooperation between jordan...
Strengthening research. development and innovation cooperation between jordan...SRTD _ II
 
A study platform to generate brand specific influenza vaccine effectiveness: ...
A study platform to generate brand specific influenza vaccine effectiveness: ...A study platform to generate brand specific influenza vaccine effectiveness: ...
A study platform to generate brand specific influenza vaccine effectiveness: ...DRIVE research
 
IPPOSI Patient Education Programme - 2017/2018 pilot
IPPOSI Patient Education Programme - 2017/2018 pilotIPPOSI Patient Education Programme - 2017/2018 pilot
IPPOSI Patient Education Programme - 2017/2018 pilotipposi
 
Presentation on Data4Impact methodology and results (Workshop in Brussels)
Presentation on Data4Impact methodology and results (Workshop in Brussels)Presentation on Data4Impact methodology and results (Workshop in Brussels)
Presentation on Data4Impact methodology and results (Workshop in Brussels)Data4Impact
 

Similar a Drive communication plan and debate - Sharon McHale & Riia Järvenpää (20)

Dissemination of Pilot Year Outcomes - Communications Workshop, Work Package 5
Dissemination of Pilot Year Outcomes - Communications Workshop, Work Package 5Dissemination of Pilot Year Outcomes - Communications Workshop, Work Package 5
Dissemination of Pilot Year Outcomes - Communications Workshop, Work Package 5
 
Connected health data meets the people: Diversity, Standards, and Trust
Connected health data meets the people: Diversity, Standards, and TrustConnected health data meets the people: Diversity, Standards, and Trust
Connected health data meets the people: Diversity, Standards, and Trust
 
Communications and Knowledge management in the African Chicken Genetic Gains ...
Communications and Knowledge management in the African Chicken Genetic Gains ...Communications and Knowledge management in the African Chicken Genetic Gains ...
Communications and Knowledge management in the African Chicken Genetic Gains ...
 
2022 IPPOSI Industry Round Table Presentation
2022 IPPOSI Industry Round Table Presentation2022 IPPOSI Industry Round Table Presentation
2022 IPPOSI Industry Round Table Presentation
 
Introduction to DRIVE - Javier Diez Domingo
Introduction to DRIVE - Javier Diez DomingoIntroduction to DRIVE - Javier Diez Domingo
Introduction to DRIVE - Javier Diez Domingo
 
Roundtable discussion: Relevance of the DRIVE study platform and sustainabili...
Roundtable discussion: Relevance of the DRIVE study platform and sustainabili...Roundtable discussion: Relevance of the DRIVE study platform and sustainabili...
Roundtable discussion: Relevance of the DRIVE study platform and sustainabili...
 
Communications and knowledge management in the African Chicken Genetic Gains ...
Communications and knowledge management in the African Chicken Genetic Gains ...Communications and knowledge management in the African Chicken Genetic Gains ...
Communications and knowledge management in the African Chicken Genetic Gains ...
 
HSE Digital Academy - Marie Boran, IPPOSI
HSE Digital Academy - Marie Boran, IPPOSIHSE Digital Academy - Marie Boran, IPPOSI
HSE Digital Academy - Marie Boran, IPPOSI
 
Delivering the gender platform’s outcomes: Communications and engagement
Delivering the gender platform’s outcomes: Communications and engagementDelivering the gender platform’s outcomes: Communications and engagement
Delivering the gender platform’s outcomes: Communications and engagement
 
Evaluating the value of research-by-consortium: Science of Team Science
Evaluating the value of research-by-consortium: Science of Team ScienceEvaluating the value of research-by-consortium: Science of Team Science
Evaluating the value of research-by-consortium: Science of Team Science
 
Analytics Management Framework
Analytics Management FrameworkAnalytics Management Framework
Analytics Management Framework
 
Euro-FEM Module 5: Promotion and Dissemination Planning
Euro-FEM Module 5: Promotion and Dissemination PlanningEuro-FEM Module 5: Promotion and Dissemination Planning
Euro-FEM Module 5: Promotion and Dissemination Planning
 
EPIS meeting - Dr Derick Mitchell - October 2017
EPIS meeting - Dr Derick Mitchell - October 2017EPIS meeting - Dr Derick Mitchell - October 2017
EPIS meeting - Dr Derick Mitchell - October 2017
 
AOU Data Collection Process
AOU Data Collection ProcessAOU Data Collection Process
AOU Data Collection Process
 
Alpha One Conference - IPPOSI
Alpha One Conference - IPPOSIAlpha One Conference - IPPOSI
Alpha One Conference - IPPOSI
 
Our space epart2014
Our space epart2014Our space epart2014
Our space epart2014
 
Strengthening research. development and innovation cooperation between jordan...
Strengthening research. development and innovation cooperation between jordan...Strengthening research. development and innovation cooperation between jordan...
Strengthening research. development and innovation cooperation between jordan...
 
A study platform to generate brand specific influenza vaccine effectiveness: ...
A study platform to generate brand specific influenza vaccine effectiveness: ...A study platform to generate brand specific influenza vaccine effectiveness: ...
A study platform to generate brand specific influenza vaccine effectiveness: ...
 
IPPOSI Patient Education Programme - 2017/2018 pilot
IPPOSI Patient Education Programme - 2017/2018 pilotIPPOSI Patient Education Programme - 2017/2018 pilot
IPPOSI Patient Education Programme - 2017/2018 pilot
 
Presentation on Data4Impact methodology and results (Workshop in Brussels)
Presentation on Data4Impact methodology and results (Workshop in Brussels)Presentation on Data4Impact methodology and results (Workshop in Brussels)
Presentation on Data4Impact methodology and results (Workshop in Brussels)
 

Más de DRIVE research

DRIVE CENTRAL STUDY PLATFORM: Data flow, data quality and statistical analysi...
DRIVE CENTRAL STUDY PLATFORM: Data flow, data quality and statistical analysi...DRIVE CENTRAL STUDY PLATFORM: Data flow, data quality and statistical analysi...
DRIVE CENTRAL STUDY PLATFORM: Data flow, data quality and statistical analysi...DRIVE research
 
DRIVE season 2018/2019
DRIVE season 2018/2019 DRIVE season 2018/2019
DRIVE season 2018/2019 DRIVE research
 
The Challenges of Pooling IVE estimates - Jos Nauta, Abbott
The Challenges of Pooling IVE estimates - Jos Nauta, AbbottThe Challenges of Pooling IVE estimates - Jos Nauta, Abbott
The Challenges of Pooling IVE estimates - Jos Nauta, AbbottDRIVE research
 
Previous exposure to natural infection matters, Ulrike Baum - ESCAIDE 2018
Previous exposure to natural infection matters, Ulrike Baum - ESCAIDE 2018Previous exposure to natural infection matters, Ulrike Baum - ESCAIDE 2018
Previous exposure to natural infection matters, Ulrike Baum - ESCAIDE 2018DRIVE research
 
Getting involved in DRIVE - Topi Turunen FISABIO
Getting involved in DRIVE - Topi Turunen FISABIOGetting involved in DRIVE - Topi Turunen FISABIO
Getting involved in DRIVE - Topi Turunen FISABIODRIVE research
 
Novel and innovative approaches for measuring influenza VE - Anke Stuurman P95
Novel and innovative approaches for measuring influenza VE - Anke Stuurman P95Novel and innovative approaches for measuring influenza VE - Anke Stuurman P95
Novel and innovative approaches for measuring influenza VE - Anke Stuurman P95DRIVE research
 
Brand specificities and study tools developed by DRIVE
Brand specificities and study tools developed by DRIVE Brand specificities and study tools developed by DRIVE
Brand specificities and study tools developed by DRIVE DRIVE research
 
Influenza vaccine effectiveness studies in Europe - Pasi Penttinen ECDC
Influenza vaccine effectiveness studies in Europe - Pasi Penttinen ECDCInfluenza vaccine effectiveness studies in Europe - Pasi Penttinen ECDC
Influenza vaccine effectiveness studies in Europe - Pasi Penttinen ECDCDRIVE research
 
Regulatory requirements for influenza vaccines - Marco Cavaleri EMA
Regulatory requirements for influenza vaccines - Marco Cavaleri EMARegulatory requirements for influenza vaccines - Marco Cavaleri EMA
Regulatory requirements for influenza vaccines - Marco Cavaleri EMADRIVE research
 
Introduction to DRIVE - Cedric Mahe
Introduction to DRIVE - Cedric MaheIntroduction to DRIVE - Cedric Mahe
Introduction to DRIVE - Cedric MaheDRIVE research
 

Más de DRIVE research (10)

DRIVE CENTRAL STUDY PLATFORM: Data flow, data quality and statistical analysi...
DRIVE CENTRAL STUDY PLATFORM: Data flow, data quality and statistical analysi...DRIVE CENTRAL STUDY PLATFORM: Data flow, data quality and statistical analysi...
DRIVE CENTRAL STUDY PLATFORM: Data flow, data quality and statistical analysi...
 
DRIVE season 2018/2019
DRIVE season 2018/2019 DRIVE season 2018/2019
DRIVE season 2018/2019
 
The Challenges of Pooling IVE estimates - Jos Nauta, Abbott
The Challenges of Pooling IVE estimates - Jos Nauta, AbbottThe Challenges of Pooling IVE estimates - Jos Nauta, Abbott
The Challenges of Pooling IVE estimates - Jos Nauta, Abbott
 
Previous exposure to natural infection matters, Ulrike Baum - ESCAIDE 2018
Previous exposure to natural infection matters, Ulrike Baum - ESCAIDE 2018Previous exposure to natural infection matters, Ulrike Baum - ESCAIDE 2018
Previous exposure to natural infection matters, Ulrike Baum - ESCAIDE 2018
 
Getting involved in DRIVE - Topi Turunen FISABIO
Getting involved in DRIVE - Topi Turunen FISABIOGetting involved in DRIVE - Topi Turunen FISABIO
Getting involved in DRIVE - Topi Turunen FISABIO
 
Novel and innovative approaches for measuring influenza VE - Anke Stuurman P95
Novel and innovative approaches for measuring influenza VE - Anke Stuurman P95Novel and innovative approaches for measuring influenza VE - Anke Stuurman P95
Novel and innovative approaches for measuring influenza VE - Anke Stuurman P95
 
Brand specificities and study tools developed by DRIVE
Brand specificities and study tools developed by DRIVE Brand specificities and study tools developed by DRIVE
Brand specificities and study tools developed by DRIVE
 
Influenza vaccine effectiveness studies in Europe - Pasi Penttinen ECDC
Influenza vaccine effectiveness studies in Europe - Pasi Penttinen ECDCInfluenza vaccine effectiveness studies in Europe - Pasi Penttinen ECDC
Influenza vaccine effectiveness studies in Europe - Pasi Penttinen ECDC
 
Regulatory requirements for influenza vaccines - Marco Cavaleri EMA
Regulatory requirements for influenza vaccines - Marco Cavaleri EMARegulatory requirements for influenza vaccines - Marco Cavaleri EMA
Regulatory requirements for influenza vaccines - Marco Cavaleri EMA
 
Introduction to DRIVE - Cedric Mahe
Introduction to DRIVE - Cedric MaheIntroduction to DRIVE - Cedric Mahe
Introduction to DRIVE - Cedric Mahe
 

Último

ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu Medical University
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 

Último (20)

ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
Mental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil ThirusanguMental health Team. Dr Senthil Thirusangu
Mental health Team. Dr Senthil Thirusangu
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 

Drive communication plan and debate - Sharon McHale & Riia Järvenpää

  • 1. Dissemination of Pilot Year Outcomes Communications Workshop Work Package 5 DRIVE Annual Forum 18 September 2018
  • 2. • WP5 introductions • DRIVE communication channels • High-level dissemination plan • Q&A • Group Activity • Group Presentations • Wrap-Up Agenda
  • 3. DRIVE Website at www.drive-eu.org • Features all public deliverables • Information on Data source, Methodology, Governance model, Analytical model and Infrastructure of the project
  • 5. DRIVE at Twitter: @drive_eu #DRIVEflu
  • 6. Web-based survey of PHIs & PHAs N=7 to date Current IVE communications adequate: >50% yes Additional IVE info required: age/risk, type, brand Recommended communication channels: conferences, publications, direct, news releases, websites, social media Frequency: regular/monthly about DRIVE activities Intention to share DRIVE results with stakeholders: yes Concerns: 1 about PPP, 1 about reconciliation of DRIVE findings with findings of other IVE studies Communications Survey
  • 7. DRIVE Stakeholders DRIVE IMI European Science, Medicine & Health Societies Society at large ECDC WHO EMA CHMP Vaccine Manufacturers Public Health Institutes National Health Agencies European Commission European Patient & Consumer Health Groups European Medical & Nursing Schools HCPs Layer 3 Layer 1 European Influenza experts Research Partners & Collaborators Media Layer 2
  • 8. Dissemination Objectives Primary Objective Ensure pilot year outcomes are communicated in a meaningful way to all stakeholder groups Secondary Objectives 1. Fulfil DRIVE’s commitment to transparency 2. Strengthen the profile and credibilty of DRIVE as public- private partnership dedicated to brand-specific IVE 3. Recruit additional research partners to DRIVE 4. Stimulate scientific discussion about innovative approaches to IVE research and potential synergies
  • 9. Communications Challenges 1. Diverse technical understanding of stakeholders 2. Potential for misinterpretation of IVE estimates 3. Perception of public-private partnerships 3. Uncoordinated disemmination of outcomes
  • 10. Key Messages 1. DRIVE is an IMI-funded public private partnership established in 2017 to build a sustainable platform for generating robust brand-specific influenza vaccine effectiveness data across Europe each year, as part of new EMA requirements. 2. DRIVE has established Project Governance, including an independent scientific review process, and an initial study platform, which was successfully tested through a pilot study in the 2017/18 season. 3. DRIVE calls for additional research partners to contribute data and expertise, enabling the Project to continue to improve the study platform and to work towards its longer term goal.
  • 11. • Study Reports and Summaries • Results Slide Presentation & Poster • Infographics Key Communication Tools
  • 13. High Level Plan Annual Forum Sept 17-18 Present Outcomes Seek feedback on Communications approach Execute Social Media Plan Study Reports Finalised October ESCAIDE Host webinars Direct email to Stakeholders Issues New Release Load reports onto DRIVE website Execute Social Media Plan Conferences & Publications 2019 Direct approach to potential partners
  • 14. Annual pooled brand-specific IVE estimates Systematic review on bias & confounders Availability & use of brand information Laboratory methods Other methodological topics (sample size, pooling approaches etc.) The rationale of brand-specific IVE and PPP governance Scientific independence, intergrity & transparency Potential publications
  • 15. Q&A
  • 16. Acknowledgement DRIVE project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777363, This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. Communications – Interactive session Acknowledgement DRIVE project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777363, This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA. Gael Dos Santos - GSK 18th September 2018, Rome
  • 17. Instructions • Each group will brainstorm for 30’ to discuss what your stakeholder group would like to know from DRIVE about IVE. • Prepare a few bullet points for presentation highlighting the key points. • Each group will have a slot of 5’ divided as follows: • At the beginning of the work, each group need to assign: - One time keeper - One scribe/presenter - The facilitators for each group have been identified on the list.
  • 18. Assigned groups 1. Regulatory Authorities – Pieter Neels 2. Public Health Institutes (PHI)/ National and supranational public health organisations Caterina Rizzo 3. Health Care Professionals - Topi Turunen 4. Researchers/Scientists Group 1 - Margarita Riera 5. Researchers/Scientists Group 2 - Marianne Van der Sande 6. Patients/Patient Organisations - Sam Nye 7. Media - Julien Guyomard
  • 19. Questions to consider? - What would I like to know about the DRIVE IVE and when? - Are there any particular sensitivities/issues/risks about communicating to my stakeholder? - Does the Public Private Partnership matter? Why?